A Rollover Study to Provide Continued Treatment With M6620 (ATRi Transition Rollover Study)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs M 6620 (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck KGaA
- 12 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Dec 2017 Planned initiation date changed from 15 Nov 2017 to 12 Jan 2018.
- 18 Oct 2017 New trial record